1207344-05-5

Basic information

• Product Name: (R)-α-Phenylcyclohexaneglycolic Acid 4-(DiethylaMino)-2-butynyl Ester, Hydrochloride
• Synonyms: SWIJYDAEGSIQPZ-FTBISJDPSA-N
• CAS NO: 1207344-05-5
• Molecular Formula: C22H32ClNO3
• Molecular Weight: 393.94738
• Product Categories: Chiral Reagents;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 1207344-05-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (R)-α-Phenylcyclohexaneglycolic Acid 4-(DiethylaMino)-2-butynyl Ester, Hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-α-Phenylcyclohexaneglycolic Acid 4-(DiethylaMino)-2-butynyl Ester, Hydrochloride(1207344-05-5)
• EPA Substance Registry System: (R)-α-Phenylcyclohexaneglycolic Acid 4-(DiethylaMino)-2-butynyl Ester, Hydrochloride(1207344-05-5)

Safety Data

• Hazardous Substances Data: 1207344-05-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(R)-α-Phenylcyclohexaneglycolic Acid 4-(DiethylaMino)-2-butynyl Ester, Hydrochloride is used as a pharmaceutical agent for the treatment of various conditions related to bladder smooth muscle cells. Its ability to inhibit proliferation and suppress gene expression makes it a promising candidate for the development of new therapeutic strategies to manage and treat bladder-related disorders.
Used in Research and Development:
In the field of research and development, (R)-α-Phenylcyclohexaneglycolic Acid 4-(DiethylaMino)-2-butynyl Ester, Hydrochloride serves as a valuable tool for studying the molecular mechanisms underlying the regulation of gene expression and cell proliferation in bladder smooth muscle cells. (R)-α-Phenylcyclohexaneglycolic Acid 4-(DiethylaMino)-2-butynyl Ester, Hydrochloride can be utilized to investigate the pathways and targets involved in these processes, potentially leading to the discovery of novel therapeutic approaches for related conditions.
Used in Drug Delivery Systems:
Similar to gallotannin, (R)-α-Phenylcyclohexaneglycolic Acid 4-(DiethylaMino)-2-butynyl Ester, Hydrochloride can also be incorporated into drug delivery systems to enhance its bioavailability, delivery, and therapeutic outcomes. By employing various organic and metallic nanoparticles as carriers, the compound's efficacy against specific cellular targets can be improved, making it a more effective treatment option for bladder-related conditions.

Upstream product

• 10575-25-4 4-diethylamino-2-butyn-1-ol 
• 303036-79-5 C₂₄H₃₄O₇ 
• 1233868-75-1 5-cyclohexyl-5-phenyl-1,3-dioxolane-2,4-dione 
• 20585-34-6 (S)-cyclohexylmandelic acid 
• 22396-77-6 acetic acid-(4-diethylamino-but-2-ynyl ester) 
• 10399-13-0 methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate 
• 5633-20-5 oxybutynin 

Relevant articles and documents

POLYMORPHIC FORMS OF (R)-OXYBUTYNIN HYDROCHLORIDE

Polymorphic forms of (R)-oxybutynin HC1, including three crystalline forms, are prepared and characterized. Uses of the various polymorphic forms of (R)-oxybutynin HC1 for Obstructive Sleep Apnea (OS A) treatment are also disclosed.

Formation of (S)-5-cyclohexyl-5-phenyl-1,3-dioxolane-2,4-dione: A key intermediate in the synthesis of (S)-oxybutynin hydrochloride

The synthesis of the drug candidate (S)-oxybutynin hydrochloride 1 is described. The procedure involves initial activation of (S)-cyclohexylmandelic acid 2, using isobutylchloroformate, followed by reaction of the resulting intermediate with 4-(diethylami

SUBSTITUTED PHENYLCYCLOHEXYLGLYCOLATES

Disclosed herein are substituted phenylcyclohexylglycolate-based muscarinic acetylcholine receptor modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

CRYSTALLINE OXYBUTYNIN AND PROCESS FOR PREPARING THE SAME

The present invention relates to a crystalline oxybutynin base and process for preparing the same. Further, this invention discloses a process for preparing an acid addition salt of oxybutynin employing the crystalline oxybutynin base.